Literature DB >> 22388891

Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma.

Luca Busino1, Scott E Millman, Luigi Scotto, Christos A Kyratsous, Venkatesha Basrur, Owen O'Connor, Alexander Hoffmann, Kojo S Elenitoba-Johnson, Michele Pagano.   

Abstract

Fbxw7α is a member of the F-box family of proteins, which function as the substrate-targeting subunits of SCF (Skp1/Cul1/F-box protein) ubiquitin ligase complexes. Using differential purifications and mass spectrometry, we identified p100, an inhibitor of NF-κB signalling, as an interactor of Fbxw7α. p100 is constitutively targeted in the nucleus for proteasomal degradation by Fbxw7α, which recognizes a conserved motif phosphorylated by GSK3. Efficient activation of non-canonical NF-κB signalling is dependent on the elimination of nuclear p100 through either degradation by Fbxw7α or exclusion by a newly identified nuclear export signal in the carboxy terminus of p100. Expression of a stable p100 mutant, expression of a constitutively nuclear p100 mutant, Fbxw7α silencing or inhibition of GSK3 in multiple myeloma cells with constitutive non-canonical NF-κB activity results in apoptosis both in cell systems and xenotransplant models. Thus, in multiple myeloma, Fbxw7α and GSK3 function as pro-survival factors through the control of p100 degradation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388891      PMCID: PMC3339029          DOI: 10.1038/ncb2463

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  45 in total

1.  Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.

Authors:  U Senftleben; Y Cao; G Xiao; F R Greten; G Krähn; G Bonizzi; Y Chen; Y Hu; A Fong; S C Sun; M Karin
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

2.  Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism.

Authors:  Benjamin Mordmüller; Daniel Krappmann; Meral Esen; Elmar Wegener; Claus Scheidereit
Journal:  EMBO Rep       Date:  2003-01       Impact factor: 8.807

3.  A fourth IkappaB protein within the NF-kappaB signaling module.

Authors:  Soumen Basak; Hana Kim; Jeffrey D Kearns; Vinay Tergaonkar; Ellen O'Dea; Shannon L Werner; Chris A Benedict; Carl F Ware; Gourisankar Ghosh; Inder M Verma; Alexander Hoffmann
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

4.  RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100.

Authors:  Emmanuel Derudder; Emmanuel Dejardin; Linda L Pritchard; Douglas R Green; Marie Korner; Veronique Baud
Journal:  J Biol Chem       Date:  2003-04-21       Impact factor: 5.157

5.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

6.  Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways.

Authors:  Brian Zarnegar; Jeannie Q He; Gagik Oganesyan; Alexander Hoffmann; David Baltimore; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

Review 7.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.

Authors:  Markus Welcker; Bruce E Clurman
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

8.  Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways.

Authors:  Jürgen R Müller; Ulrich Siebenlist
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

9.  Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis.

Authors:  Ichiro Onoyama; Ryosuke Tsunematsu; Akinobu Matsumoto; Taichi Kimura; Ignacio Moreno de Alborán; Keiko Nakayama; Keiichi I Nakayama
Journal:  J Exp Med       Date:  2007-11-12       Impact factor: 14.307

10.  The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.

Authors:  Benjamin J Thompson; Silvia Buonamici; Maria Luisa Sulis; Teresa Palomero; Tomas Vilimas; Giuseppe Basso; Adolfo Ferrando; Iannis Aifantis
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

View more
  99 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  The non-canonical NF-κB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro.

Authors:  Kira Meyerovich; Makiko Fukaya; Leticia F Terra; Fernanda Ortis; Decio L Eizirik; Alessandra K Cardozo
Journal:  Diabetologia       Date:  2015-12-03       Impact factor: 10.122

3.  FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.

Authors:  Rizwan Saffie; Nan Zhou; Delphine Rolland; Özlem Önder; Venkatesha Basrur; Sydney Campbell; Kathryn E Wellen; Kojo S J Elenitoba-Johnson; Brian C Capell; Luca Busino
Journal:  Cancer Res       Date:  2020-04-29       Impact factor: 12.701

4.  IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors.

Authors:  Hélène Authier; Katy Billot; Emmanuel Derudder; Didier Bordereaux; Pierre Rivière; Sylvie Rodrigues-Ferreira; Clara Nahmias; Véronique Baud
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

Review 5.  The role of aberrant proteolysis in lymphomagenesis.

Authors:  Anagh A Sahasrabuddhe; Kojo S J Elenitoba-Johnson
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

6.  Preventing abnormal NF-κB activation and autoimmunity by Otub1-mediated p100 stabilization.

Authors:  Yanchuan Li; Jin-Young Yang; Xiaoping Xie; Zuliang Jie; Lingyun Zhang; Jianhong Shi; Daniel Lin; Meidi Gu; Xiaofei Zhou; Haiyan S Li; Stephanie S Watowich; Antrix Jain; Sung Yun Jung; Jun Qin; Xuhong Cheng; Shao-Cong Sun
Journal:  Cell Res       Date:  2019-05-13       Impact factor: 25.617

7.  PARP1-dependent recruitment of the FBXL10-RNF68-RNF2 ubiquitin ligase to sites of DNA damage controls H2A.Z loading.

Authors:  Gergely Rona; Domenico Roberti; Yandong Yin; Julia K Pagan; Harrison Homer; Elizabeth Sassani; Andras Zeke; Luca Busino; Eli Rothenberg; Michele Pagano
Journal:  Elife       Date:  2018-07-09       Impact factor: 8.140

8.  Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.

Authors:  Sushil Kumar; Ratnesh Kumar Srivastava; Snahlata Singh; Ajeya Nandi; Gatha Thacker; Hemma Murali; Sabrina Kim; Mary Baldeon; John Tobias; Mario Andres Blanco; Rizwan Saffie; M Raza Zaidi; Satrajit Sinha; Luca Busino; Serge Y Fuchs; Rumela Chakrabarti
Journal:  Nat Cell Biol       Date:  2020-04-13       Impact factor: 28.824

Review 9.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

10.  Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.

Authors:  Maryna Gorelik; Stephen Orlicky; Maria A Sartori; Xiaojing Tang; Edyta Marcon; Igor Kurinov; Jack F Greenblatt; Mike Tyers; Jason Moffat; Frank Sicheri; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.